. . "Posaconazole is eliminated with a mean half-life (t½) of 35 hours (range 20 to 66 hours)."@en . . . . . "The excreted metabolites in urine and feces account for ~17% of the administered radiolabeled dose."@en . "171228-49-2"@en . "investigational"@en . . . . "Dominic De Souza, \"PREPARATION OF POSACONAZOLE INTERMEDIATES.\" U.S. Patent US20130203994, issued August 08, 2013."@en . . . . . . . "* 32 L/hr * 51 L/hr [Single-Dose Suspension Administration of 200 mg, fasted] * 21 L/hr [Single-Dose Suspension Administration of 200 mg, nonfat meal] * 14 L/hr [Single-Dose Suspension Administration of 200 mg, high fat meal] * 91 L/hr [Single-Dose Suspension Administration of 400 mg, fasted] * 43 L/hr [Single-Dose Suspension Administration of 400 mg with liquid nutritional supplement (14 g fat)]"@en . . . . . "approved"@en . "Posaconazole is absorbed with a median Tmax of approximately 3 to 5 hours."@en . "SID144207169"@en . "# Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348-59. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17251531 # Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17251530 # Bhattacharya M, Rajeshwari K, Dhingra B: Posaconazole. J Postgrad Med. 2010 Apr-Jun;56(2):163-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20622401 # Frampton JE, Scott LJ: Posaconazole : a review of its use in the prophylaxis of invasive fungal infections. Drugs. 2008;68(7):993-1016. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18457464 # Schiller DS, Fung HB: Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007 Sep;29(9):1862-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18035188 # Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17516880 # Groll AH, Walsh TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16107193 # Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH: Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother. 2008 Oct;42(10):1429-38. Epub 2008 Aug 19. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18713852 # Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H: Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20481649"@en . "Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients."@en . . . . . . "Posaconazole is highly protein bound (>98%), predominantly to albumin."@en . . "* 1774 L"@en . "During the clinical trials, some patients received posaconazole up to 1600 mg/day with no adverse events noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg BID for 3 days. No related adverse events were noted by the investigator."@en . . . . . . . "Aspergillis, Candida and other fungi"@en . . . . . . . . . . . "As a triazole antifungal agent, posaconazole exerts its antifungal activity through blockage of the cytochrome P-450 dependent enzyme, sterol 14α-demethylase, in fungi by binding to the heme cofactor located on the enzyme. This leads to the inhibition of the synthesis of ergosterol, a key component of the fungal cell membrane, and accumulation of methylated sterol precursors. This results in inhibition of fungal cell growth and ultimately, cell death."@en . . . . " "@en . . . . . "Posaconazole"@en . . . "For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals."@en . . . . . . .